Home›Stocks›RGNX

RGNX — structural market context

REGENXBIO Inc.

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 22. Each line shows the earlier value, the later value and their dates.

Price

Close $7.17 (Oct 22) vs $7.17 (Oct 21): 0.00%.

Volume

0.77× its 20-session average (1.5M) on Oct 22.

Includes pre- and post-market trading.

Short interest

Short interest 9.6M shares (settlement Sep 30) vs 7.9M (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 15–Sep 30, published Oct 16): 1 day with fails, largest 25K shares on Sep 30.

Previous file (settlements Sep 1–Sep 14, published Sep 30): 1 day with fails, largest 193 shares on Sep 4.

No new publication in this window.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

None recorded in this window.

RGNX events and their magnitude

Latest SEC filing in the event study

8-K 5.02 · Executive or director change · filed 2026-10-16 · View on sec.gov ↗

…

Open the Event Study →

RGNX short interest & days to cover

SHARES SHORT
9.6M
% OF FLOAT
16.8%
DAYS TO COVER
6.0
CHANGE VS PRIOR
+21.2%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (23d ago)

RGNX fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-30 · 23d25K$7.45
2026-09-04 · 49d193$9.2
2026-08-13 · 71d26K$10.91

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

RGNX insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 2 purchases · 0 sales

InsiderTypeSharesValueFiled
Ciongoli Gregory Austin · directorPurchase (P)53K$500K2026-08-27
Ciongoli Gregory Austin · directorPurchase (P)49K$450K2026-08-27

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

RGNX analyst ratings

FirmActionRatingPublished
Mizuho Securitiesprice_target—2026-10-05
H.C. WainwrightholdBuy2026-09-28
H.C. Wainwrightprice_target—2026-08-25
Robert W. Bairdprice_target—2026-08-25

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

What is RGNX's short interest?
As of the FINRA settlement date 2026-09-30, RGNX had 9.6M shares sold short — 16.8% of its float, with 6.0 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.
Are insiders buying RGNX?
In the last 12 months of SEC Form 4 filings, RGNX recorded 2 insider purchases and 0 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
What do analysts say about RGNX?
The most recent action: Mizuho Securities price_target on 2026-10-05. Rating actions are shown as published by the firms; they are not graded here.
Is this page telling me to buy or sell RGNX?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with R

RAL · Ralliant CorporationRCUS · Arcus Biosciences, Inc.RDDT · Reddit, Inc.RDEIY · Redeia Corporacion SARGLD · Royal Gold, Inc.RKLB · Rocket Lab CorporationAll R →

RGNX: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.